
NASDAQHealthcareMedical - Instruments & Supplies
ข้อมูลล่าสุด
US$3.90
+US$0.105 · +2.77%
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
ข้อมูลล่าสุด
US$3.90
+US$0.105 · +2.77%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
47
มูลค่ายุติธรรม
ความเชื่อมั่น
57
ผสม
ความเสี่ยง
41
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
61
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 115.02M USD | 185.83M USD | 405.47M USD | 387.48M USD | 233.67M USD |
| ต้นทุนสินค้าขาย | 66.82M USD | 109.6M USD | 226.05M USD | 239.04M USD | 116.07M USD |
| กำไรขั้นต้น | 48.2M USD | 76.23M USD | 179.42M USD | 148.44M USD | 117.6M USD |
| การวิจัยและพัฒนา | 42.53M USD | 24.42M USD | 33.16M USD | 36.24M USD | 34.17M USD |
| การขาย ทั่วไป และธุรการ | 73.79M USD | 72.41M USD | 92.18M USD | 117.44M USD | 95.08M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 116.32M USD | 96.83M USD | 125.34M USD | 153.68M USD | 129.25M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 10.19M USD | 10.87M USD | 20.94M USD | 15.54M USD | 11.66M USD |
| รายได้จากการดำเนินงาน | −68.12M USD | −20.6M USD | 54.08M USD | −5.24M USD | −11.65M USD |
| รายได้สุทธิ | −68.73M USD | −19.5M USD | 53.66M USD | −17.13M USD | −23M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$4.00
โอกาสปรับขึ้น 2.56%| รายการ | วันที่มีผลบังคับใช้ | รายละเอียด | วันกำหนดรายชื่อ | วันจ่ายเงิน |
|---|---|---|---|---|
การแยกหุ้น | 8 เม.ย. 2530 | 3:1 | — | — |
มีผลแล้ว 8 เม.ย. 2530
3:1
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI7.71M0.00%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM6.34M0.01%78.74B USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF2.89M0.00%95.4B USD0.05%US$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2.45M0.01%26.81B USD0.33%US$37.95-0.39%
Dimensional - US Small Cap ETFDFAS2.03M0.01%33.87B USD0.31%US$78.35+0.32%
Vanguard Russell 2000 ETFVTWO1.35M0.01%18B USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1.28M0.01%21.82B USD0.03%US$32.79+0.40%
Dimensional - US Core Equity 2 ETFDFAC1.01M0.00%88.6B USD0.21%US$45.33+0.49%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Dimensional - US Core Equity 2 ETFDFACเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน